Implementing positive psychiatry approaches can face various barriers across different levels of care. These include resistance to change, limited resources, time constraints, and the dominance of a deficit-focused model. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how to address these […]

Positive psychiatry encompasses several approaches that focus on promoting well-being and resilience in mental health care. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how positive psychiatry can be effectively integrated into clinical practice to manage patient outcomes and well-being, and […]

In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. The abstract entitled “XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, […]

The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy.   In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses this clinical trial and the outcomes of its open-label extension.  The […]

Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]

The discovery of ketamine’s therapeutic potential for psychiatric disorders changed the field of mental health, since nearly every FDA-approved medication for schizophrenia and mood disorders targeted monoamine signaling, i.e., dopamine, serotonin, and norepinephrine. As ketamine was initially used as an anaesthetic, ketamine’s ability to modulate monoamine signaling pathways emerged, leading to ground-breaking breakthroughs. In this […]

The discovery of the rapid antidepressant effects of ketamine shifted the biology and treatment of psychiatric disorders, emphasizing targeting glutamate signaling, rather than monoamine signaling, for schizophrenia and depression. Research highlights synaptic deficits, network disinhibition, and synaptic loss in schizophrenia, while identifying glutamate synaptic dysfunction and the efficacy of ketamine for depression. In this touchNEUROLOGY […]

Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]

Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]